Loading
Shattuck Labs, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Ashiya Mona, was filed 02 Sept 2025.
Shattuck Labs, Inc.: what insiders have been doing
Shattuck Labs, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 6 insiders have disclosed 17 filings since 21 October 2025.
The flow runs one way only: 2 sales worth €171k, from 2 insiders, and no purchase. The largest single trade was a sale of €169k by Pandite Arundathy N., published on 14 May 2026, equal to 0.026% of the market capitalisation.
Compared with its exchange (5,814 companies, median 19 filings), a count of 17 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 8 purchases and 31 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 1.0 m USD and net income at -48.8 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
102
Thresholds
n/a
Buy Volume
€5M
8 ops. · all time
Sell Volume
€4M
31 ops. · all time
Who traded when
BuySaleMona Ashiya2 buys
Abhinav A. Shukla1 sale
Arundathy N. Pandite1 sale
Orbimed Advisors LLC1 buy
Redmile Group, LLC1 sale
Since the insiders bought
- +443.8%Entry US$1.28 · Close at T+365 US$6.96
- -23.7%Entry US$3.93 · Close at T+365 US$3.00
- -58.8%Entry US$6.91 · Close at T+365 US$2.85
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Shattuck Labs, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$15.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.33
Analyst consensus
10 analystsStrong buy
US$10.00Target US$15.40(+189%)US$19.00
Income statement
RevenueUS$1M
EBITDA-US$47.8M-4782% margin
Net income-US$48.8M-4880.9% margin
Valuation
PER (forward)-10.3x
P/Book2.5x
Beta1.10
Balance sheet & cash
Market capUS$534.9M
Total debtUS$2.4M
Free Cash Flow-US$40M
Debt / Equity1%
Profitability & ownership
ROE-39.2%
ROA-24.4%
% insiders4.1%
% institutions80.2%
Last declaration on 7 July 2026
Declarations102 total
410 shares@ US$3.570.0002% mcap0.6% of flowCommon StockSEC:0001193125-26-297768:0
12,153 shares@ US$3.570.0068% mcap19.0% of flowCommon StockSEC:0001193125-26-297768:2
410 shares@ US$7.010.0005% mcap1.3% of flowCommon StockSEC:0001193125-26-297768:1
410 shares@ US$7.00940.0005% mcap1.3% of flowCommonSEC144:0001959173-26-005072
100 shares@ US$7.070.0001% mcap0.3% of flowCommonSEC144:0001959173-26-005028
23,365 shares@ US$7.08190.026% mcap72.5% of flowCommonSEC144:0001959173-26-004975
2,032 shares@ US$3.570.0009% mcap3.1% of flowCommon StockSEC:0001193125-26-224686:0
64,027 shares@ US$1.08460.0090% mcap18.4% of flowCommon StockSEC:0001193125-26-224692:0
30,000 shares@ US$6.610.026% mcap81.2% of flowCommon StockSEC:0001193125-26-224669:0
2,589 shares@ US$4.152.8% of flowCommon StockSEC:0001193125-26-024393:0
593 shares@ US$4.157.3% of flowCommon StockSEC:0001193125-26-024424:0
2,286 shares@ US$4.1525.8% of flowCommon StockSEC:0001193125-26-024409:0
3,195 shares@ US$4.155.4% of flowCommon StockSEC:0001193125-26-024489:0
4,153 shares@ US$4.7559.2% of flowCommon StockSEC:0001193125-26-011860:0
5,699 shares@ US$4.7574.2% of flowCommon StockSEC:0001193125-26-011853:0
6,851 shares@ US$4.7513.4% of flowCommon StockSEC:0001193125-26-011837:0
6,660 shares@ US$4.758.5% of flowCommon StockSEC:0001193125-26-011828:0
5,255,106 shares@ US$0.867783.3% of flowCommon StockSEC:0000947871-25-000839:0
Canonical exit: 23 Nov 2025 (T+90)
1,051,021 shares@ US$0.867716.7% of flowCommon StockSEC:0000947871-25-000839:1
Canonical exit: 23 Nov 2025 (T+90)
5,255,106 shares@ US$0.8677100.0% of flowCommon StockSEC:0000947871-25-000840:0
Canonical exit: 23 Nov 2025 (T+90)
12,805 shares@ US$0.867733.5% of flowCommon StockSEC:0001193125-25-189086:0
64,027 shares@ US$0.867714.9% of flowCommon StockSEC:0001193125-25-189088:0
25,610 shares@ US$0.86772.7% of flowCommon StockSEC:0001193125-25-189087:0
128,054 shares@ US$0.8677100.0% of flowCommon StockSEC:0001193125-25-189085:0
5,122 shares@ US$0.86771.9% of flowCommon StockSEC:0001193125-25-189084:0
25 of 102 declarations
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (ticker: STTK) is a U.S.-listed biotechnology company traded on NASDAQ in the United States. Founded in 2016, the company is organized around research and development operations in Durham, North Carolina, and a corporate office in Austin, Texas. Its business is centered on the discovery and development of potential therapies for inflammatory and immune-mediated diseases, positioning Shattuck as a clinical-stage biotech rather than a commercial-stage pharmaceutical company. For investors, the key question is not current product revenue, but rather the probability that one or more of its pipeline assets can generate clinically meaningful data and ultimately create licensing or commercial value.
Scientifically, Shattuck Labs has built its strategy around the biology of TNF superfamily receptors, especially the DR3/TL1A signaling axis. The company describes itself as developing next-generation monoclonal and bispecific antibodies designed to modulate these pathways. Its lead program is SL-325, a first-in-class DR3 blocking antibody being advanced in inflammatory disease indications. This focus is important because the company has recently sharpened its pipeline strategy, emphasizing immunology and inflammation after prioritizing programs and discontinuing others. That narrower focus can improve capital efficiency, but it also increases dependence on a small number of clinical assets.
Read moreShow less
From a competitive standpoint, Shattuck Labs remains a small-cap biotech with meaningful execution risk. It is not a diversified large pharma group and does not have a broad commercial portfolio to cushion setbacks. Its market position is therefore defined by scientific differentiation, clinical milestones, and the ability to extend cash runway. In the highly competitive immunology landscape, the company’s challenge is to generate data strong enough to stand out against larger peers developing therapies for similar inflammatory and autoimmune indications. At the same time, its DR3-focused approach gives it a more focused narrative than many platform biotechs.
Recent developments have been material. In its March 2026 year-end update, Shattuck said SL-325 Phase 1 enrollment was nearing completion, with human data expected in the second quarter of 2026 and a Phase 2 trial in Crohn’s disease expected to start in the third quarter of 2026. The company also disclosed a strengthened balance sheet after recent capital raises and said its current cash resources, together with proceeds from an at-the-market facility and assuming warrant exercise, were expected to fund operations into 2029 under its plans. For international equity investors, STTK is a classic development-stage biotech story: high risk, binary clinical catalysts, and potential upside tied to proof-of-concept execution on NASDAQ in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
